“Rapid progress” towards a COVID-19 vaccine candidate sparked a Canadian biopharma stock Tuesday. Here’s some small stocks making big moves on Tuesday, July 14, 2020 (as of 4 pm EST):
IMV Inc. (TSX:IMV), a Canadian biopharma stock, surged 57% to $6.35 on Tuesday after announcing further details on what the Company calls “rapid progress” in developing its candidate vaccine to prevent COVID-19 infection, which includes an agreement with Health Canada on a Phase 1 clinical study design protocol that also includes patients 56 years and older.
As well, shares of Calfrac Well Services Ltd. (TSX:CFW) fell 18% to $0.14 as the provider of specialized oilfield services said it has obtained a preliminary court order to restructure certain debt obligations, which would lead to a recapitalization transaction.
Pascal Biosciences Inc. (TSXV:PAS), meanwhile, reported that it has discovered certain cannabinoids that block replication of SARS-CoV-2, the coronavirus that causes COVID-19. Pascal Biosciences stock popped 26% to $0.315 following the announcement.
Finally, Northern Vertex Mining Corp. (TSXV:NEE) shares gained 6% to $0.37 after the junior precious metals miner announced record production of 11,365 gold equivalent ounces in addition to record revenue of US$18.2 million for the quarter ended June 30 from its 100% owned Moss Gold Mine in Arizona.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
IMV Inc. (TSX:IMV), a Canadian biopharma stock, surged 57% to $6.35 on Tuesday after announcing further details on what the Company calls “rapid progress” in developing its candidate vaccine to prevent COVID-19 infection, which includes an agreement with Health Canada on a Phase 1 clinical study design protocol that also includes patients 56 years and older.
, on Tuesday.){kind=link}